Marilu Henner Encourages Tough Talks on Bladder Cancer

May 17, 2017
by Stephanie Chisolm

For Bladder Cancer Awareness Month, BCAN and actress Marilu Henner have partnered with Genentech, a member of the Roche group, to share her personal story and help people navigate challenging – but necessary – conversations about bladder cancer. Marilu knows firsthand the importance of these discussions. In 2003, she and her now husband Michael Brown were on vacation when she learned he had blood in his urine. Michael had told his urologist about this symptom before Marilu knew about it, but the urologist told him it was nothing to worry about. “I am incredibly dedicated to my health and the…

Read More...

FDA Approves PD-L1 Inhibitor Avelumab (BAVENCIO) for Bladder Cancer

May 9, 2017
by Alejandra Spangler

The PD-L1 inhibitor avelumab (BAVENCIO) has been granted accelerated approval by the Food and Drug Administration. This treatment by Pfizer, Inc. and EMD Serono is targeted to patients with locally advanced or metastatic urothelial carcinoma with disease progression during or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. “Until recently, there had been limited innovation in urothelial carcinoma, and this approval gives us another treatment to help battle this aggressive disease.” – Andrea Apolo, MD, medical oncologist at the National Cancer Institute and member of our Scientific Advisory Board Click below to read EMD Serono’s Press Release…

Read More...

FDA accelerates approval of IMFINZI (durvalumab)

May 3, 2017
by Alejandra Spangler

The Food and Drug Administration grants an accelerated approval of IMFINZI (durvalumab), a breakthrough therapy for previously treated advanced bladder cancer patients. This therapy focuses on identifying and attacking cancer cells by restoring the immune system.  This is AstraZeneca’s first approved Immuno-Oncology (IO) therapy.   “We are excited to offer Imfinzi as a breakthrough therapy for patients with locally-advanced or metastatic bladder cancer. Imfinzi is the cornerstone of our extensive Immuno-Oncology programme, in development across many tumour types, as monotherapy and in combination. This first approval for Imfinzi is an important milestone in our return to growth and brings us another step closer…

Read More...

TURBT is Important

April 20, 2017
by Stephanie Chisolm

URO Today article notes that the precise and thorough resection (TURBT) of all existing tumors remains a critical factor influencing bladder cancer patient outcomes. It can not only reduce the incidence of under-staging, but also can provide the optimal setting for adjuvant therapy (additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back.) Enhanced cystoscopy has a critical role to play in helping urologists in this area, as recommended by the updated AUA/SUO guidelines on NMIBC.   Read the article by BCAN Scientific Advisory Board member Ashish Kamat, MD and Kamal Pohar, MD here. Share this page:

Read More...

Great news! Expanding options in immunotherapy

April 18, 2017
by Stephanie Chisolm

The FDA Granted Genentech’s Tecentriq (Atezolizumab) Accelerated Approval as Initial Treatment for Certain People with Advanced Bladder Cancer. “It is encouraging to see continued progress in the treatment of advanced bladder cancer, which until last year had not seen any major advancements in more than 30 years,” said Andrea Maddox Smith, chief executive officer, Bladder Cancer Advocacy Network. “We are excited that TECENTRIQ is now a treatment option for people with advanced bladder cancer who are unable to receive a cisplatin-based chemotherapy as an initial treatment.” Read more. Share this page:

Read More...

BCAN Launches My Bladder Cancer Story

February 21, 2017
by Stephanie Chisolm

This year, over 79,000 people will be diagnosed with bladder cancer. BCAN understands that there are real people behind this number. Our ‘My Bladder Cancer Story’ Campaign presents stories to raise awareness and call attention to the lives and daily experiences of bladder cancer patients and families nationwide. Read the stories            Share your Story Share this page:

Read More...

Join BCAN for a New Discoveries Research Lecture in Palm Beach March 8th, 2017

February 8, 2017
by Stephanie Chisolm

On March 8th, 2017 the Bladder Cancer Advocacy Network New Discoveries Research Luncheon & Lecture will give attendees a glimpse into some of the new treatments used to combat the fifth most commonly diagnosed cancer in the country. The lecture and luncheon will take place at The Beach Club in Palm Beach, Florida, and will feature Dr. David McConkey, Director of Johns Hopkins Greenberg Bladder Cancer Institute, who will highlight promising new bladder cancer treatments, as well as Fay Vincent, former Major League Baseball Commissioner, and bladder cancer survivor who will share his personal journey. 11:30 AM-1:30 PM, Wednesday, March 8, 2017 at The…

Read More...

BMS Receives FDA Approval for Opdivo (nivolumab) in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma

February 3, 2017
by Stephanie Chisolm

BCAN applauds the U.S. Food and Drug Administration (FDA) for approving Opdivo for use for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. “Although bladder cancer is the 5th most commonly diagnosed cancer in the United States, it is only recently that we are starting to see new treatments being approved to help patients with this disease,” according to Andrea Maddox-Smith, CEO of BCAN.  “The FDA’s approval of Opdivo offers a much-needed treatment option for the…

Read More...

UPDATE on Camp Lejeune Water Contamination and Bladder Cancer

January 19, 2017
by Stephanie Chisolm

Between 1957 and 1987, people serving or living at the U.S. Marine Corps Base Camp Lejeune, North Carolina, were potentially exposed to drinking water contaminated with industrial solvents, benzene, and other chemicals. This chemical exposure may have led to adverse health conditions.On 1/13/2017 – The Department of Veterans Affairs (VA)  published regulations to establish presumptions for the service connection of bladder cancer and seven other diseases associated with exposure to contaminants in the water supply at Camp Lejeune, N.C. Read more here: VA’s Rule Establishes a Presumption of Service Connection for Diseases Associated with Exposure to Contaminants in the Water Supply…

Read More...

BCAN Launches Winter Webinar Series!

December 13, 2016
by Stephanie Chisolm

Wondering what to do on chilly winter nights this January and February? Wish you knew more about bladder cancer? Sign up now for our Bladder Cancer 2017 Winter Webinar Series. We bring the experts to you! You don’t even have to shovel the walk or leave your home to join us for these free Patient Insight Webinars. Make some hot chocolate, grab a blanket and your computer. Leading bladder cancer experts will answer your questions about pathology, bladder removal, and sexuality. To see the full details and to register Click here   Share this page:

Read More...